Vera Therapeutics, Inc. Unrealized Gain (Loss) on Investments
Vera Therapeutics, Inc. (VERA) reported Unrealized Gain (Loss) on Investments of -$247.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Operating Activities
us-gaap:UnrealizedGainLossOnInvestments · last filed 2026-08-10
- Vera Therapeutics, Inc. unrealized gain (loss) on investments for the quarter ending 2026-06-30 was -$247.00K.
- Vera Therapeutics, Inc. unrealized gain (loss) on investments for the quarter ending 2026-03-31 was -$942.00K, a 460.92% decline year-over-year.
- Vera Therapeutics, Inc. unrealized gain (loss) on investments for the quarter ending 2025-09-30 was $354.00K, a 76.31% decline year-over-year.
- Vera Therapeutics, Inc. unrealized gain (loss) on investments for the quarter ending 2025-06-30 was -$127.00K.
- Vera Therapeutics, Inc. unrealized gain (loss) on investments for fiscal 2025 was $393.00K, a 176.76% increase from fiscal 2024.
- Vera Therapeutics, Inc. unrealized gain (loss) on investments for fiscal 2024 was $142.00K, a 70.11% decline from fiscal 2023.
- Vera Therapeutics, Inc. unrealized gain (loss) on investments for fiscal 2023 was $475.00K.
- Vera Therapeutics, Inc. unrealized gain (loss) on investments for fiscal 2022 was -$224.00K.
| Period end | Unrealized Gain (Loss) on Investments 3 month | Unrealized Gain (Loss) on Investments 6 month | Unrealized Gain (Loss) on Investments 9 month | Unrealized Gain (Loss) on Investments 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$247.00K 10-Q · filed 2026-08-10 | -$1.19M derived: sum of 2 quarters · filed 2026-08-10 | ||
| 2026-03-31 | -$942.00K 10-Q · filed 2026-08-10 | |||
| 2025-12-31 | $393.00K 10-K · filed 2026-02-26 | |||
| 2025-09-30 | $354.00K 10-Q · filed 2025-11-05 | $227.00K derived: sum of 2 quarters · filed 2026-08-10 | $488.00K derived: sum of 3 quarters · filed 2026-08-10 | |
| 2025-06-30 | -$127.00K 10-Q · filed 2026-08-10 | $134.00K derived: sum of 2 quarters · filed 2026-08-10 | ||
| 2025-03-31 | $261.00K 10-Q · filed 2026-08-10 | |||
| 2024-12-31 | $142.00K 10-K · filed 2026-02-26 | |||
| 2024-09-30 | $1.49M 10-Q · filed 2025-11-05 | $1.22M derived: sum of 2 quarters · filed 2025-11-05 | $793.00K derived: sum of 3 quarters · filed 2025-11-05 | |
| 2024-06-30 | -$277.00K 10-Q · filed 2025-11-05 | -$701.00K derived: sum of 2 quarters · filed 2025-11-05 | ||
| 2024-03-31 | -$424.00K 10-Q · filed 2025-11-05 | |||
| 2023-12-31 | $475.00K 10-K · filed 2026-02-26 | |||
| 2023-09-30 | $67.00K 10-Q · filed 2024-11-07 | -$71.00K derived: sum of 2 quarters · filed 2024-11-07 | $149.00K derived: sum of 3 quarters · filed 2024-11-07 | |
| 2023-06-30 | -$138.00K 10-Q · filed 2024-11-07 | $82.00K derived: sum of 2 quarters · filed 2024-11-07 | ||
| 2023-03-31 | $220.00K 10-Q · filed 2024-11-07 | |||
| 2022-12-31 | -$224.00K 10-K · filed 2024-03-27 | |||
| 2022-09-30 | -$127.00K 10-Q · filed 2023-11-09 | -$267.00K derived: sum of 2 quarters · filed 2023-11-09 | -$279.00K derived: sum of 3 quarters · filed 2023-11-09 | |
| 2022-06-30 | -$140.00K 10-Q · filed 2023-11-09 | -$152.00K derived: sum of 2 quarters · filed 2023-11-09 | ||
| 2022-03-31 | -$12.00K 10-Q · filed 2023-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |